Drugs · acquisition-cost intelligence
erythromycin
· ingredient erythromycinAntibiotics· ERYTHROMYCIN 250 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$5.96
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 5 weeks.
2025-12-172026-04-22
Same-ingredient options by acquisition cost
Other erythromycin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| erythromycin | $0.34583 | −$5.61 |
| Erythromycin | $0.66199 | −$5.30 |
| Ery | $1.24 | −$4.72 |
| E.E.S | $1.59 | −$4.37 |
| erythromycin | $2.86 | −$3.10 |
| Erythromycin | $2.87 | −$3.09 |
| Erythromycin | $2.97 | −$2.99 |
| ERY-TAB | $2.97 | −$2.99 |
Medicare Part D coverage · CY2026
On 192 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.